Merryl Cramer

AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)

Patrick P. Zarrinkar, Ruwanthi N. Gunawardane, Merryl Cramer et al. · Blood · 2009 · 630 citations · Full text

Identification of <i>N</i>-(5-<i>tert</i>-Butyl-isoxazol-3-yl)-<i>N</i>′-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-<i>b</i>][1,3]benzothiazol-2-yl]phenyl}urea Dihydrochloride (AC220), a Uniquely Potent, Selective, and Efficacious FMS-Like Tyrosine Kinase-3 (FLT3) Inhibitor

Qi Chao, Kelly G. Sprankle, Robert M. Grotzfeld et al. · Journal of Medicinal Chemistry · 2009 · 189 citations · Full text

Drug Target, Aml Patients, Pharmacotherapy +20

Identification of 1-(3-(6,7-Dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea Hydrochloride (CEP-32496), a Highly Potent and Orally Efficacious Inhibitor of V-RAF Murine Sarcoma Viral Oncogene Homologue B1 (BRAF) V600E

Martin W. Rowbottom, Raffaella Faraoni, Qi Chao et al. · Journal of Medicinal Chemistry · 2011 · 58 citations · Full text

Orally Efficacious Inhibitor, Chemoprevention Strategy, Immunology +19

Biphenyl-indanones: Allosteric potentiators of the metabotropic glutamate subtype 2 receptor

Céline Bonnefous, Jean‐Michel Vernier, John H. Hutchinson et al. · Bioorganic & Medicinal Chemistry Letters · 2005 · 50 citations

Allosteric Potentiators, Molecular Pharmacology, G Protein-coupled Receptor +8

CEP-32496: A Novel Orally Active BRAFV600E Inhibitor with Selective Cellular and <i>In Vivo</i> Antitumor Activity

Joyce James, Bruce Ruggeri, Robert C. Armstrong et al. · Molecular Cancer Therapeutics · 2012 · 47 citations · Full text

Tumor Biology, Active Braf Inhibitor, Novel Therapy +15